U.S. Healthtech Stock News

NYSE:PRM
NYSE:PRMChemicals

Perimeter Solutions Balances Sauget Setbacks With Acquisition And Contract Shift

Perimeter Solutions (NYSE:PRM) is dealing with operational and safety issues at its Sauget P2S5 facility that have led to reduced production and ongoing litigation as it seeks to take control of the site. The company has recently closed a sizeable acquisition while shifting more of its portfolio toward fixed and recurring contracts to support more consistent earnings. These developments affect a key production asset and the structure of Perimeter Solutions' revenue, with potential...
NYSE:UGI
NYSE:UGIGas Utilities

How Investors May Respond To UGI (UGI) Distribution Rate Hike Suspension And Gas Cost Increases

In recent weeks, UGI Utilities has begun additional natural gas system upgrades in Lancaster and implemented higher purchased gas cost rates, while its proposal for a US$99.40 million annual distribution rate increase has been temporarily suspended by the Pennsylvania Public Utility Commission for further review. Together, these infrastructure investments, customer bill impacts, and regulatory oversight highlight how UGI’s earnings profile is closely tied to state-level rate decisions and...
NYSE:IDA
NYSE:IDAElectric Utilities

Will Strong 2025 Earnings and New 2026 EPS Guidance Change IDACORP's (IDA) Narrative?

IDACORP, Inc. recently reported its full-year 2025 results, with sales of US$1.81 billion, revenue of US$1.81 billion, and net income rising to US$323.47 million, alongside higher basic and diluted earnings per share from continuing operations compared with 2024. At the same time, the company issued 2026 earnings guidance of US$6.25 to US$6.45 per diluted share, highlighting management’s expectations while signaling limited use of additional tax credits under Idaho’s regulatory...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Regeneron News Highlights Rare Disease Focus And Valuation Gap

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis, a chronic nasal disease. The FDA also accepted garetosmab for Priority Review for treating fibrodysplasia ossificans progressiva, a rare and serious genetic disorder. For you as an investor, these decisions highlight where Regeneron focuses its efforts: targeted biologic therapies in areas with limited existing options. Dupixent already sits at the center...
NasdaqGS:SIRI
NasdaqGS:SIRIMedia

Is It Time To Reassess Sirius XM (SIRI) After Recent Share Price Weakness?

If you are wondering whether Sirius XM Holdings is still priced fairly after everything that has happened to the stock, this article walks through what the current share price could mean for long term investors. The stock recently closed at US$21.96, with returns of 4.3% over 7 days and 7.9% over 30 days, while the 1 year return sits at a 4.5% decline and the 3 and 5 year returns are 42.3% and 55.6% declines. Those mixed returns have arrived against a backdrop of ongoing product, content and...
NasdaqGS:SONO
NasdaqGS:SONOConsumer Durables

Assessing Sonos (SONO) Valuation After New Agentic AI Initiative With EXL And AWS

Sonos (SONO) has become a talking point after EXL announced a transformation initiative with Sonos and Amazon Web Services to deploy agentic AI within Sonos IT service management workflows, targeting efficiency, operational intelligence, and risk mitigation. See our latest analysis for Sonos. The latest AI initiative sits against a mixed share price backdrop, with Sonos trading at US$15.40 and showing a 7.3% 1 month share price return but a 17% 3 month share price decline. The 1 year total...
NasdaqGS:SHC
NasdaqGS:SHCLife Sciences

Assessing Sotera Health (SHC) Valuation After Strong 2025 Results And 2026 Growth Guidance

Sotera Health (SHC) shares were in focus after the company reported stronger fourth quarter and full year 2025 earnings and provided new 2026 revenue guidance, outlining expected net revenues of US$1.233b to US$1.251b. See our latest analysis for Sotera Health. The recent earnings beat, new 2026 revenue guidance and upcoming leadership change around the General Counsel role arrive after a softer patch for the stock, with a 30 day share price return of 10.32% decline and a 1 year total...
NasdaqGS:EBC
NasdaqGS:EBCBanks

Reassessing Eastern Bankshares (EBC) After Recent Weakness And Conflicting Valuation Signals

If you are wondering whether Eastern Bankshares is fairly priced at its current level, this article walks through what the numbers are saying about its valuation. The stock last closed at US$19.56, with returns of an 8.7% decline over 7 days, a 4.5% decline over 30 days, a 5.5% gain year to date, 12.7% over 1 year, 34.2% over 3 years, and 23.6% over 5 years. This mix of shorter term weakness and longer term gains has put valuation back in focus for many investors, who may be reassessing how...
NYSE:MO
NYSE:MOTobacco

Is It Time To Reassess Altria Group (MO) After Strong Share Price Gains?

If you are wondering whether Altria Group's share price still lines up with its underlying value, this article walks through the key numbers that matter before you make any big calls. Altria Group recently closed at US$69.04, with returns of 2.2% over 7 days, 11.4% over 30 days, 20.5% year to date, 32.5% over 1 year, 88.4% over 3 years and 125.9% over 5 years. These figures raise fair questions about how the current price compares to estimated fair value. Recent news coverage has focused on...
NYSE:RYN
NYSE:RYNSpecialized REITs

Is Rayonier (RYN) Now Offering Value After Recent Share Price Weakness

If you are wondering whether Rayonier's current share price reflects its underlying value, this article will walk through what the numbers are actually saying. At a last close of US$21.49, Rayonier's shareholders have seen a 5.2% decline over the past week and a 5.5% decline over 30 days. The stock is also lower over 1 year, 3 years, and 5 years. These recent returns have put more attention on how Rayonier is being valued and what expectations are built into the current price. With the share...
NYSE:UBER
NYSE:UBERTransportation

A Look At Uber Technologies (UBER) Valuation After Uber Air And Robotaxi Expansion

Uber Technologies (UBER) has moved beyond traditional ride hailing with two headline launches: Uber Air with Joby Aviation in Dubai and Uber Autonomous Solutions for commercializing robotaxis across multiple markets. See our latest analysis for Uber Technologies. Despite a stream of announcements around Uber Air, autonomous charging hubs, and the new Uber Autonomous Solutions platform, momentum in the share price has cooled, with a 30 day share price return of 5.78% decline and a year to date...
NYSE:FRO
NYSE:FROOil and Gas

Frontline (FRO) Is Up 9.3% After Q4 Earnings Beat And Accelerated VLCC Fleet Renewal – What's Changed

In late February 2026, Frontline plc reported fourth-quarter 2025 results showing revenue of US$624.51 million and net income of US$227.93 million, with earnings of US$1.02 per share from continuing operations. Alongside the earnings beat, Frontline accelerated a major fleet renewal by selling eight older VLCCs and acquiring nine scrubber-fitted eco-VLCC newbuildings, signaling a shift toward a younger, more fuel-efficient tanker portfolio. Next, we’ll examine how this fleet renewal,...
NasdaqGS:NMRK
NasdaqGS:NMRKReal Estate

Is It Time To Reassess Newmark Group (NMRK) After Recent Share Price Weakness?

If you are wondering whether Newmark Group's share price reflects its underlying worth today, you are not alone. This article is set up to help you frame that question clearly. The stock recently closed at US$14.52, with returns of a 3.8% decline over 7 days, 18.6% decline over 30 days, 14.4% decline year to date and 0.2% decline over the past year, while the 3 year and 5 year returns sit at 89.2% and 50.1% respectively. These moves have put valuation back in focus for Newmark Group...
NasdaqGS:APP
NasdaqGS:APPSoftware

How Investors Are Reacting To AppLovin (APP) Record Q4, AI Pivot and Rising Regulatory Scrutiny

In February 2026, AppLovin reported its strongest quarter to date, with Q4 2025 revenue of US$1.7 billion and EPS of US$3.24, both above prior Wall Street forecasts, while guiding Q1 2026 revenue to US$1.75 billion–US$1.78 billion and continuing its pivot toward an AI-driven, high-margin adtech platform. At the same time, the company’s transformation away from gaming and toward its AXON AI engine and e‑commerce advertising is being weighed against regulatory scrutiny, including an active SEC...
NasdaqGS:SSNC
NasdaqGS:SSNCProfessional Services

Assessing SS&C Technologies (SSNC) After Recent Share Price Weakness And DCF Upside Potential

If you are wondering whether SS&C Technologies Holdings is offering fair value at its current price, or if the market is mispricing it, this article walks through the key numbers that matter for you as a shareholder or potential investor. The stock last closed at US$75.29, with a recent 5.5% gain over 7 days sitting against a 12.2% decline year to date and a 14.4% decline over the past year. The 3 year and 5 year returns are 31.4% and 21.6% respectively. These mixed returns sit alongside an...
NasdaqGS:LAUR
NasdaqGS:LAURConsumer Services

How Laureate Education’s Bigger Buyback and 2026 Outlook At Laureate Education (LAUR) Has Changed Its Investment Story

On 19 February 2026, Laureate Education reported fourth-quarter 2025 results showing higher sales and earnings per share than a year earlier, issued first-quarter and full-year 2026 revenue guidance, and disclosed completion of a US$218.89 million buyback under its existing program. On the same day, the company also expanded its capital return plans by increasing its share repurchase authorization to US$400 million, signaling management’s confidence in its financial capacity while it...
NasdaqGS:GLXY
NasdaqGS:GLXYCapital Markets

Galaxy Digital Expands Into AI While Valuation Lags Analyst Target

Galaxy Digital (NasdaqGS:GLXY) is expanding into AI and high performance computing data center infrastructure at its Helios campus. The company also plans to launch GalaxyOne in October 2025, a fintech platform that connects traditional and digital asset markets. These moves signal a broader business focus beyond Galaxy Digital's existing digital asset activities. For you as an investor looking at crypto and digital asset firms, Galaxy Digital sits at the intersection of trading, asset...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

How Investors Are Reacting To SPS Commerce (SPSC) Earnings Beat, Revenue Miss, and CEO Stock Sale

SPS Commerce recently reported quarterly results that beat earnings-per-share expectations but slightly trailed revenue forecasts, while its CEO Chadwick Collins sold about US$785,000 of stock under a pre-arranged plan and management presented at the Morgan Stanley Technology, Media & Telecom Conference. The mixed earnings outcome, analyst downgrade citing softer 2026 expectations, and insider sale together raise fresh questions about the strength and timing of SPS Commerce’s growth...
NYSE:UTZ
NYSE:UTZFood

Utz Brands Taps Protein And Premium Chips To Support Margin Story

Utz Brands (NYSE:UTZ) introduced new protein-enriched snacks under the Utz brand at the 2026 Natural Products Expo West. The company also rolled out Boulder Canyon Agave Sriracha kettle chips, positioned around gluten-free and non-GMO attributes. These launches target consumer interest in high-protein, better-for-you salty snacks with globally inspired flavors. Utz Brands, known for its salty snacks portfolio across brands such as Utz and Boulder Canyon, is leaning into demand for higher...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

Rhythm Pharmaceuticals Nears Key FDA Calls With Global Growth Potential

Rhythm Pharmaceuticals is moving toward a key FDA decision for IMCIVREE in acquired hypothalamic obesity, with preparations underway for a potential U.S. approval and commercial launch. The company has received constructive FDA feedback at its end of Phase 2 meeting for oral candidate bivamelagon, supporting plans to progress into Phase 3. Rhythm is also working on broader commercial access, reimbursement, and geographic expansion in Europe and Japan for its rare neuroendocrine disease...
NYSE:CRBG
NYSE:CRBGDiversified Financial

Reassessing Corebridge Financial (CRBG) Valuation After Recent Share Price Weakness

Why Corebridge Financial Is Back On Investors’ Radar Corebridge Financial (CRBG) has drawn fresh attention after a period of weak share performance, including negative moves over the past week, month and past 3 months, prompting investors to reassess its fundamentals and valuation. See our latest analysis for Corebridge Financial. The recent 1 day share price return of negative 7.35%, extending to a 30 day share price return of negative 16.19%, suggests momentum has faded in the short term...
NasdaqGS:HNST
NasdaqGS:HNSTPersonal Products

Honest Company (HNST) Valuation Check After Wider Loss Lower Revenue And New US$25m Buyback

Honest Company (HNST) has drawn fresh attention after reporting full year 2025 results that show lower sales and a wider net loss, along with new 2026 guidance and a US$25 million share repurchase program. See our latest analysis for Honest Company. At a share price of US$2.80, recent moves have been mixed, with a strong 7 day share price return of 23.35% and a 30 day share price return of 13.36%. However, a 1 year total shareholder return decline of 48.15% suggests longer term holders have...
NasdaqGM:GCT
NasdaqGM:GCTRetail Distributors

A Look At GigaCloud Technology (GCT) Valuation After Record Results And New Buyback Program

GigaCloud Technology (GCT) drew fresh attention after reporting record Q4 and full year 2025 results, pairing higher revenue and earnings with new Q1 revenue guidance and a sizable share repurchase program. See our latest analysis for GigaCloud Technology. GigaCloud Technology's share price has been volatile around these results, with a 26.58% 7 day share price return and 16.38% 90 day share price return. The 1 year total shareholder return is 161.90%, which hints at strong positive momentum...
NYSE:APAM
NYSE:APAMCapital Markets

Assessing Artisan Partners (APAM) Valuation After Recent Share Price Pullback And Modest Undervaluation Signals

Recent price moves and financial snapshot Artisan Partners Asset Management (APAM) has seen its share price decline about 2.5% over the past day and roughly 9.5% over the past month, putting recent trading action on many investors’ radar. At a last close of US$40.28, the US based investment manager reports annual revenue of about US$1.2b and net income of roughly US$265.9m. See our latest analysis for Artisan Partners Asset Management. While the 1 month share price return of Artisan Partners...